Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial — Jean-François Dhainaut (2003) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
Shared by
Jean Louis Vincent
Université Libre de Bruxelles
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
Article
2003
en
Authors
+8 more
JD
Jean-François Dhainaut
PL
Pierre‐François Laterre
JJ
Jonathan Janes
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2003
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*
Jean Louis Vincent
,
Derek C. Angus
,
Antonio Artigas
,
André C. Kalil
,
Bruce R. Basson
,
Hassan H. Jamal
,
Gerald D. Johnson
,
Gordon R. Bernard
Article
2006
Drotrecogin alfa (activated) in the treatment of severe sepsis
Jean Louis Vincent
Article
2007
Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Jean Louis Vincent
Article
2007
Drotrecogin alfa (activated): the treatment for severe sepsis?
Jean Louis Vincent
Article
2004
The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
Jean Louis Vincent
,
Gordon R. Bernard
,
Jean François Dhainaut
,
Mitchell M. Levy
,
Arthur P. Wheeler
,
William L. Macias
Discussion(0)
No comments yet. Be the first to comment.